| Biotechnology feed | All feeds
Price target increased from $54 to $70.
Auriga analyst says, "Based on our checks, we are increasing our Tyvaso numbers for Q4 2009 from $5.3MM to ... Street Insider: Jan 13 2010 4:46PM Matching: remodulin Find similar documents
Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.
All rights reserved. All other trademarks recognized. Copyright 1997-2009 - BioPortfolio Limited.
